{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:20:45Z","timestamp":1790677245037,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.07.049","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T16:45:11Z","timestamp":1563813911000},"page":"5323-5331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up"],"prefix":"10.1016","volume":"37","author":[{"given":"Stephane","family":"Carryn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-7073","authenticated-orcid":false,"given":"Muriel","family":"Feyssaguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Povey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.07.049_b0005","unstructured":"Centers for disease control and prevention. Measles cases and outbreaks, https:\/\/www.cdc.gov\/measles\/cases-outbreaks.html; 2018 [accessed 16 January 2019]."},{"key":"10.1016\/j.vaccine.2019.07.049_b0010","unstructured":"Centers for disease control and prevention. Chapter 20: Rubella. In: Epidemiology and prevention of vaccine-preventable diseases, 13th Edition \u201cThe Pink Book\u201d: Centers for Disease Control and Prevention; 2012. p. 325\u201340."},{"key":"10.1016\/j.vaccine.2019.07.049_b0015","unstructured":"Centers for disease control and prevention. Mumps cases and outbreaks, https:\/\/www.cdc.gov\/mumps\/outbreaks.html; 2018 [accessed 16 January 2019]."},{"key":"10.1016\/j.vaccine.2019.07.049_b0020","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.15585\/mmwr.mm6642a6","article-title":"Progress toward regional measles elimination - worldwide, 2000\u20132016","volume":"66","author":"Dabbagh","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.07.049_b0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.15585\/mmwr.mm6529a2","article-title":"Mumps outbreak at a university and recommendation for a third dose of measles-mumps-rubella vaccine - Illinois, 2015\u20132016","volume":"65","author":"Albertson","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.07.049_b0030","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.1016\/j.vaccine.2009.06.109","article-title":"Mumps resurgences in the United States: A historical perspective on unexpected elements","volume":"27","author":"Barskey","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.049_b0035","unstructured":"World Health Organization. Measles cases hit record high in the European Region, http:\/\/www.euro.who.int\/en\/media-centre\/sections\/press-releases\/2018\/measles-cases-hit-record-high-in-the-european-region, http:\/\/www.euro.who.int\/en\/media-centre\/sections\/press-releases\/2018\/measles-cases-hit-record-high-in-the-european-region; 2018 [Accessed 13 December 2018] [accessed 13 December 2018]."},{"key":"10.1016\/j.vaccine.2019.07.049_b0040","unstructured":"Centers for disease control and prevention. Measles cases and outbreaks, https:\/\/www.cdc.gov\/measles\/cases-outbreaks.html, https:\/\/www.cdc.gov\/measles\/cases-outbreaks.html; 2018 [Accessed 16 January 2019] [accessed 16 January 2019]."},{"key":"10.1016\/j.vaccine.2019.07.049_b0045","unstructured":"Centers for disease control and prevention. Mumps cases and outbreaks, https:\/\/www.cdc.gov\/mumps\/outbreaks.html, https:\/\/www.cdc.gov\/mumps\/outbreaks.html; 2018 [Accessed 16 January 2019] [accessed 16 January 2019]."},{"key":"10.1016\/j.vaccine.2019.07.049_b0050","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0140-6736(90)90420-A","article-title":"Immunisation and herd immunity","volume":"335","author":"Anderson","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.07.049_b0055","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJMoa0706589","article-title":"Recent resurgence of mumps in the United States","volume":"358","author":"Dayan","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.07.049_b0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5945","article-title":"Vaccine waning and mumps re-emergence in the United States","author":"Lewnard","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.07.049_b0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15585\/mmwr.mm6701a7","article-title":"Recommendation of the advisory committee on immunization practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak","volume":"67","author":"Marin","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.07.049_b0070","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1086\/528993","article-title":"Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up","volume":"197","author":"Davidkin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.049_b0075","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.vaccine.2017.11.081","article-title":"One or two doses of live varicella virus-containing vaccines: efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life","volume":"36","author":"Henry","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.049_b0080","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1473-3099(18)30716-3","article-title":"Protection against varicella with one or two doses of live varicella virus-containing vaccines: 10-years follow-up of a multicentre, observer-blind, randomised, controlled trial of children vaccinated in the second year of life","volume":"19","author":"Povey","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.049_b0085","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(12)61461-5","article-title":"Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial","volume":"383","author":"Prymula","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.07.049_b0090","unstructured":"European Medicines Agency. Priorix. Annex III: Summary of product characteristics, labelling and package leaflet; 2012, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Priorix_30\/WC500124199.pdf, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Priorix_30\/WC500124199.pdf; [Accessed 15 January 2019] [accessed 15 January 2018]."},{"key":"10.1016\/j.vaccine.2019.07.049_b0095","unstructured":"GlaxoSmithKline. Priorix-Tetra. Summary of product characteristics; 2017, https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_MT\/PDF\/Homepage\/Products\/productlisting\/priorix-tetra\/Priorix_Tetra_PI_II_078_18_Apr_2017.pdf, https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_MT\/PDF\/Homepage\/Products\/productlisting\/priorix-tetra\/Priorix_Tetra_PI_II_078_18_Apr_2017.pdf; [Accessed 12 December 2018] [accessed 12 December 2018]."},{"key":"10.1016\/j.vaccine.2019.07.049_b0100","unstructured":"GlaxoSmithKline. Varilrix. Summary of product characteristics; 2018. https:\/\/www.medicines.org.uk\/emc\/product\/1676\/smpc, https:\/\/www.medicines.org.uk\/emc\/product\/1676\/smpc; [Accessed 12 December 2018] [accessed 12 December 2018]."},{"key":"10.1016\/j.vaccine.2019.07.049_b0105","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1016\/j.vaccine.2009.07.076","article-title":"A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile","volume":"27","author":"Czajka","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.049_b0110","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1017\/S0950268818001474","article-title":"Post-immunisation fever and the antibody response to measles-containing vaccines","volume":"146","author":"Carazo Perez","year":"2018","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2019.07.049_b0115","doi-asserted-by":"crossref","first-page":"30156","DOI":"10.2807\/1560-7917.ES.2016.21.10.30156","article-title":"Waning immunity against mumps in vaccinated young adults, France 2013","volume":"21","author":"Vygen","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2019.07.049_b0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fphys.2017.00233","article-title":"Waning immunity is associated with periodic large outbreaks of mumps: a mathematical modeling study of Scottish data","volume":"8","author":"Hamami","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.vaccine.2019.07.049_b0125","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.vaccine.2017.12.075","article-title":"Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine","volume":"36","author":"Seagle","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.049_b0130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1201-9712(02)90112-8","article-title":"A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children","volume":"6","author":"Lee","year":"2002","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.049_b0135","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/INF.0b013e318170bb22","article-title":"Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life","volume":"27","author":"Schuster","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.07.049_b0140","first-page":"49","article-title":"Mumps vaccines: WHO position paper","volume":"82","author":"World Health Organization","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2019.07.049_b0145","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.07.049_b0150","first-page":"2624","article-title":"Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study","volume":"14","author":"Abu-Elyazeed","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.07.049_b0155","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa1703309","article-title":"Effectiveness of a third dose of MMR vaccine for mumps outbreak control","volume":"377","author":"Cardemil","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.07.049_b0160","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/INF.0b013e318279f593","article-title":"Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control\u2013Guam 2009 to 2010","volume":"32","author":"Nelson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.07.049_b0165","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1542\/peds.2012-0177","article-title":"Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak","volume":"130","author":"Ogbuanu","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2019.07.049_b0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2004.12.010","article-title":"Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children","volume":"115","author":"Dhiman","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.07.049_b0175","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1086\/598482","article-title":"Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination","volume":"199","author":"Vandermeulen","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.049_b0180","doi-asserted-by":"crossref","first-page":"ofu094","DOI":"10.1093\/ofid\/ofu094","article-title":"Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine","volume":"1","author":"Fiebelkorn","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.049_b0185","doi-asserted-by":"crossref","first-page":"ofx263","DOI":"10.1093\/ofid\/ofx263","article-title":"Mumps virus nucleoprotein and hemagglutinin-specific antibody response following a third dose of measles mumps rubella vaccine","volume":"4","author":"Latner","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.049_b0190","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1016\/j.vaccine.2011.04.037","article-title":"A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine","volume":"29","author":"Haralambieva","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.049_b0195","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.vaccine.2014.01.090","article-title":"Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts","volume":"32","author":"Haralambieva","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.049_b0200","first-page":"913","article-title":"Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children","volume":"11","author":"Rager-Zisman","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2019.07.049_b0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/vim.2011.0051","article-title":"Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination","volume":"25","author":"Umlauf","year":"2012","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2019.07.049_b0210","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1016\/j.vaccine.2016.08.060","article-title":"Genetically defined race, but not sex, is associated with higher humoral and cellular immune responses to measles vaccination","volume":"34","author":"Voigt","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:17Z","timestamp":1759401257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19309405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":42,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X19309405"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}